Akeso, Inc. ((HK:9926)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Akeso, Inc. (HK:9926) is conducting a Phase Ib/II clinical study titled ‘A Phase Ib/II Study of Anti-PD-1/LAG-3 Bispecific Antibody AK129 Combinations in Advanced Solid Tumors.’ The study aims to determine the recommended Phase II dose of AK129 combinations and assess their safety and efficacy in treating advanced solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, and colorectal adenocarcinoma.
The study tests AK129, a bispecific antibody, in combination with chemotherapy drugs like Pemetrexed, Paclitaxel, and Carboplatin. AK129 is designed to enhance the immune response against cancer cells.
This interventional study uses a randomized, parallel assignment model without masking and focuses on treatment. It aims to establish the effectiveness of AK129 in combination with other treatments.
The study began on April 6, 2025, with primary completion expected soon. The last update was on May 28, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
Positive results from this study could boost Akeso’s stock by enhancing its competitive position in the oncology market, potentially attracting investor interest. This is especially relevant given the competitive landscape in cancer immunotherapy.
The study is ongoing, with further details available on the ClinicalTrials portal.